| Drug ID: | Drug21 |
|---|---|
| Drug Name: | Lidocaine |
| CID: | 3676 |
| DrugBank ID: | DB00281 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00982618, , NCT01155440 |
| Molecular Formula: | C14H22N2O |
| Molecular Weight: | 234.34 g/mol |
| Isomeric SMILES: | CCN(CC)CC(=O)NC1=C(C=CC=C1C)C |
| Synonyms: | lidocaine; 137-58-6; Lignocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Duncaine; Esracaine; Xylestesin; Alphacaine; Cappicaine; Gravocain |
| Phase 0: | 63 |
| Phase 1: | 136 |
| Phase 2: | 294 |
| Phase 3: | 302 |
| Phase 4: | 557 |
| Description: | A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt189 | 3676 | Lidocaine | 6328 | SCN3A | Homo sapiens (human) | Blocker | |
| dt190 | 3676 | Lidocaine | 11280 | SCN11A | Homo sapiens (human) | 37713619 | Blocker |
| dt191 | 3676 | Lidocaine | 6336 | SCN10A | Homo sapiens (human) | Inhibitor | |
| dt192 | 3676 | Lidocaine | 6335 | SCN9A | Homo sapiens (human) | Inhibitor | |
| dt193 | 3676 | Lidocaine | 6331 | SCN5A | Homo sapiens (human) | Inhibitor | |
| dt194 | 3676 | Lidocaine | 1956 | EGFR | Homo sapiens (human) | 16551906 | Antagonist |
| dt195 | 3676 | Lidocaine | 6329 | SCN4A | Homo sapiens (human) | 14662728 | None |
| dt196 | 3676 | Lidocaine | 5004 | ORM1 | Homo sapiens (human) | 8946472 | None |
| dt197 | 3676 | Lidocaine | 5005 | ORM2 | Homo sapiens (human) | 8946472 | None |
| dt198 | 3676 | Lidocaine | 1576 | CYP3A4 | Homo sapiens (human) | Substrate |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03844412 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | PHASE2 | COMPLETED | Duke University | Vestibulodynia|Temporomandibular Disorder|Fibromy… | DRUG: 5% lidocaine/5 mg/ml 0.02% estradiol compou… | Details |
| NCT01155440 | Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine | PHASE2 | COMPLETED | McGill University Health Centre/Research Institute of the McGill University Health Centre | Colon Cancer|Inflammatory Bowel Diseases|Divertic… | DRUG: Lidocaine|PROCEDURE: Thoracic epidural block | Details |
| NCT00982618 | Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine | NA | COMPLETED | McGill University Health Centre/Research Institute of the McGill University Health Centre | Colon Cancer|Inflammatory Bowel Diseases|Divertic… | DRUG: Lidocaine|PROCEDURE: Epidural Block|DRUG: P… | Details |
| NCT00108446 | Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome | PHASE2 | COMPLETED | US Department of Veterans Affairs | Irritable Bowel Syndrome | DRUG: dextromethorphan|DRUG: naloxone|DRUG: fenta… | Details |
| CTIS2023-508224-35-01 | Analgesic effect of intravenous lidocaine and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain. | PHASE2 | Recruiting | CHU De Liege | Inflammatory Bowel disease;Therapeutic area: Dise… | Product Name: Linisol 1 %, solution injectable, P… | Details |
| ACTRN12616000478415 | Intravenous (IV) lidocaine infusions for 48 hours in open colorectal surgery: a prospective, randomised, double-blinded, placebo-controlled trial. | PHASE4 | Not Recruiting | St Vincent's Hospital Sydney Department of Anaesthesia | bowel cancer;inflammatory bowel disease;colorecta… | Patients undergoing elective open colorectal surg… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Adenosine, lidocaine, and magnesium for attenuating ischemia reperfusion injury…
PMID: 34840271
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Minimally invasive resuscitative endovascular balloon occlusion of the aorta (REBOA) following noncompressible hemorrhage results in sign…